O6‐methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study
Middleton MR. et al, (2000), International Journal of Cancer, 88, 469 - 473
Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide
Middleton MR. et al, (2000), CLINICAL CANCER RESEARCH, 6, 4574S - 4574S
Adjuvant interferon in the treatment of melanoma - Reply
Middleton MR., (2000), BRITISH JOURNAL OF CANCER, 82, 1755 - 1756
Temozolomide for advanced, metastatic melanoma - Reply
Middleton MR., (2000), JOURNAL OF CLINICAL ONCOLOGY, 18, 2185 - 2185
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma
middleton MR. et al, (2000), Journal of Clinical Oncology, 18, 1474 - 1480
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
Middleton MR. et al, (2000), Journal of Clinical Oncology, 18, 158 - 166
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Middleton MR. et al, (2000), Int J Cancer, 85, 248 - 252
O-6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts
Middleton MR. et al, (2000), INTERNATIONAL JOURNAL OF CANCER, 85, 248 - 252
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Middleton MR. et al, (2000), Cancer Chemother Pharmacol, 45, 15 - 20
Phase II trial of 4-hourly temozolomide (TMZ) in advanced malignant melanoma (MM)
Arance A. et al, (1999), EUROPEAN JOURNAL OF CANCER, 35, S371 - S371
Adjuvant interferon in the treatment of melanoma.
Middleton MR., (1999), Br J Cancer, 80, 1679 - 1680
Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics.
Lo SK. et al, (1999), Lancet, 353, 2038 - 2039
Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain.
McElhinney RS. et al, (1998), J Med Chem, 41, 5265 - 5271
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Middleton MR. et al, (1998), Br J Cancer, 78, 1199 - 1202
A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
Jayson GC. et al, (1998), Br J Cancer, 78, 366 - 369
Dose intensity in small cell lung cancer
Thatcher N. et al, (1998), Seminars in Oncology, 25, 12 - 18
Dose intensity in small cell lung cancer
Thatcher N. et al, (1998), SEMINARS IN ONCOLOGY, 25, 12 - 18
Encephalopathy and haemorrhagic mucositis after high-dose melphalan with peripheral blood stem cell rescue in two patients with impaired renal function
Schuh AH. et al, (1998), BONE MARROW TRANSPLANTATION, 21, S202 - S202